Company intelligence / Profile preview

NeuroX1

Austin, Texas, United Statesneurox1.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

NeuroX1 has developed a proprietary AI-powered drug discovery platform, Chiron, which leverages physics-based generative chemistry to design novel small molecule therapeutics for neurodegenerative and other neurological conditions. The company has several pre-clinical assets in its pipeline, some in partnership with pharma companies and institutions. No clinical results have been reported as of May 2025.[3][4][5]

Key points: Early-stage/preclinical; focus on accelerating target ID and lead optimization using AI; no clinical trial data yet.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Everlum Bio Inc. (co-development partnership for rare/neglected pediatric neurology therapeutics)[5]

Beyond the preview

Go deeper on NeuroX1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroX1.

Explore the full profile